Endocrine Abstracts

Hypophysitis is classified according to the anatomic location of pituitary involvement and the cause (primary or secondary forms). The primary forms are characterized by an idiopathic inflammatory process confined to the pituitary gland, while the secondary forms are triggered by a definite etiology. Recently, as a secondary form of hypophysitis, an immune-mediated paraneoplastic syndrome defined as paraneoplastic autoimmune hypophysitis has been reported. This novel clinical ...

Somapacitan is a long-acting, reversible albumin-binding growth hormone (GH) derivative. The objective of this trial was to evaluate the safety, efficacy and treatment satisfaction of onceweekly somapacitan versus daily GH (Norditropin) over 52 weeks in Japanese patients with adult GH deficiency (AGHD). This was a phase 3, multicentre, randomised, open-label, parallel-group, active-controlled trial (NCT03075644). Patients previously treated with GH were randomised 1:3 to daily...

Somapacitan is a once-weekly, long-acting growth hormone (GH) derivative approved for the treatment of adult GH deficiency (AGHD). Our objective was to evaluate the effects of somapacitan on glucose metabolism compared with daily GH or placebo in patients with AGHD using data from three previously published phase 3 trials: REAL 1 (NCT02229851), REAL 2 (NCT02382939) and REAL Japan (NCT03075644). REAL 1 was a randomised, placebo-controlled (double-blind) and active-controlled (o...

Introduction: Growth hormone (GH) replacement therapy is safe and confers significant benefits in body composition, bone health, cardiometabolic risk factors, and quality of life in adults with GH deficiency. However, longer term safety and efficacy data are limited by the lack of consistency in data collection between studies. The study aim was to develop a simple global register by standardising and developing a minimum data set (MDS) to facilitate international collection o...